Unfortunately, whilst we would welcome a randomised comparison of cisplatin and pemetrexed versus cisplatin and gemcitabine in this disease, this is unlikely to occur as the same pharmaceutical company manufactures both pemetrexed and gemcitabine.
1 Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009 Australia; 2 Department of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, 6009 Australia
* E-mail: anowak{at}cyllene.uwa.edu.au or Anna.Nowak{at}health.wa.gov.au
References
1. Steele JPC, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 2005; 16: 345351.
2. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999; 17: 2530.
3. Nowak AK, Byrne MJ, Williamson R et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491496.[CrossRef][ISI][Medline]
4. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer core quality of life questionnaire and lung cancer module. J Clin Oncol 2004; 22: 31723180.
5. Van Haarst JMW, Baas P, Manegold C et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86: 342345.[CrossRef][ISI][Medline]
6. Castagneto B, Zai S, Dongiovanni V et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study. Proc Am Soc Clin Oncol 2003; 22: 656 (Abstr 2637).
7. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257260.
|